NEWS
Ixabepilone
  • Approved Drug Name
    Ixabepilone
  • CAS NO.
    219989-84-1
  • Quality Standard
    Enterprise Standard
  • Packaging
    10G/Bag, 20G/Bag
  • Storage Condition
    Shading,Sealing,Cryopreservation(Below-20℃)
  • Certification
    Ongoing registration

How Does Ixabepilone(casno.219989-84-1) Given:
Ixapebilone is given as an infusion into the vein (intravenous, IV).
The amount of Ixabepilone(casno.219989-84-1) that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition you have. Your doctor will determine your exact Ixabepilone(casno.219989-84-1) dosage and schedule.
Ixabepilone(casno.219989-84-1) Side Effects:
Important things to remember about the side effects of Ixabepilone(casno.219989-84-1).
Most people will not experience all of the Ixabepilone(casno.219989-84-1) side effects listed.
Ixabepilone(casno.219989-84-1) side effects are often predictable in terms of their onset, duration, and severity.
Ixabepilone(casno.219989-84-1) side effects will improve after therapy is complete.
Ixabepilone(casno.219989-84-1) side effects may be quite manageable. There are many options to minimize or prevent the side effects of Ixabepilone(casno.219989-84-1).
The following side effects are common (occurring in greater than 30%) for patients taking Ixabepilone(casno.219989-84-1):
Peripheral neuropathy: Although uncommon a serious side effect of decreased sensation and paresthesia (numbness and tingling of the hands and feet) may be noted. Sensory loss, numbness and tingling, and difficulty in walking may last for at least as long as therapy is continued. These side effects may become progressively more severe with continued treatment, and your doctor may decide to decrease your dose.
Weakness 
Muscle and joint pains 
Hair loss 
Nausea & Vomiting
Low white blood cell count
These are less common side effects (occurring in about 10-29%) of patients receiving Ixabepilone(casno.219989-84-1):
Mouth sores 
Diarrhea
Muscle and bone pain 
Poor appetite 
Constipation
Abdominal pain 
Headache 
This list includes common and less common side effects for those taking Ixabepilone(casno.219989-84-1). Ixabepilone(casno.219989-84-1) side effects that are very rare -- occurring in less than about 10 percent of patients -- are not listed here. Always inform your health care provider if you experience any unusual symptoms.
When To Contact Your Doctor or Health Care Provider:
Ixabepilone(casno.219989-84-1) is given by intravenous infusion and you will be monitored during each infusion. Report to the nurse immediately: 
Unusual chest tightness, difficulty breathing or swallowing, itching or skin rash,back pain or headache
Redness, swelling or pain at the infusion site
Contact your doctor or health care provider immediately, day or night, if you should experience any of the following symptoms:
Fever of 100.4° F (38° C) or higher, chills (possible signs of infection)
The following symptoms require medical attention, but are not an emergency. Contact your doctor or health care provider within 24 hours of noticing any of the following:
Nausea (interferes with ability to eat and unrelieved with prescribed medication)
Vomiting (vomiting more than 4-5 times in a 24 hour period)
Diarrhea (4-6 episodes in a 24-hour period)
Extreme fatigue(unable to carry on self-care activities)
Mouth sores (painful redness, swelling or ulcers)
Difficulty breathing or unusual cough
Swelling of feet and/or legs, sudden weight gain
Unable to eat or drink for 24 hours or have signs of dehydrationsuch as: tiredness, thirst, dry mouth, dark and decrease amount of urine, or dizziness.
Always inform your doctor or health care provider if you experience any unusual symptoms.
Ixabepilone(casno.219989-84-1) Precautions:
Before starting Ixabepilone(casno.219989-84-1) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.). While taking Ixabepilone(casno.219989-84-1) do not take aspirin or products containing aspirin unless your doctor specifically permits this.
Do not drink grapefruit juice while recieving Ixabepilone(casno.219989-84-1).  Drinking grapefruit juice may cause you to have too much Ixabepilone(casno.219989-84-1) in your blood and lead to side effects. 
While taking Ixabepilone(casno.219989-84-1), do not receive any kind of immunization or vaccination without your doctor’s approval.
For both men and women: Use contraceptives and do not conceive a child (get pregnant) while taking Ixabepilone(casno.219989-84-1). Barrier methods of contraception such as condoms are recommended. Discuss with your doctor or nurse what type of birth control would be safe for you to use.
Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment.  Pregnancy category D (Ixabepilone(casno.219989-84-1) may be hazardous to the fetus.  Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus).
Do not breast feed while taking Ixabepilone(casno.219989-84-1).
Self-Care Tips While Taking Ixabepilone(casno.219989-84-1):
While taking Ixabepilone(casno.219989-84-1), try to drink at least two to three quarts of fluid every 24 hours, (particularly the 24 hours before and 48 hours following the infusion) unless you are instructed otherwise.
You may be at risk of infection so try to avoid crowds or people with colds, and report fever or any other signs of infection immediately to your health care provider.
Wash your hands often.
To help treat/prevent mouth sores while taking Ixabepilone(casno.219989-84-1), use a soft toothbrush, and rinse three times a day with 1 teaspoon of baking soda mixed with 8 ounces of water.
To reduce nausea, take anti-nausea medications as prescribed by your doctor, and eat small, frequent meals while taking Ixabepilone(casno.219989-84-1).
Avoid sun exposure. Wear SPF 15 (or higher) sunblock and protective clothing.
You may experience drowsiness or dizziness; avoid driving or engaging in tasks that require alertness until your response to the drug is known.
In general, drinking alcoholic beverages should be kept to a minimum or avoided completely while you are taking Ixabepilone(casno.219989-84-1). You should discuss this with your doctor.
keywords
Ixabepilone Quality
Ixabepilone Manufacturers
Ixabepilone Suppliers
Ixabepilone FDA
Ixabepilone USP.EP
Ixabepilone GMP
Ixabepilone price
Ixabepilone samples
Get plenty of rest.
Maintain good nutrition while being treated with Ixabepilone(casno.219989-84-1).
If you experience symptoms or side effects while being treated with Ixabepilone(casno.219989-84-1), be sure to discuss them with your health care team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.
Monitoring and Testing While Taking Ixabepilone(casno.219989-84-1):
You will be checked regularly by your doctor while you are taking Ixabepilone(casno.219989-84-1) to monitor side effects and check your response to therapy. Periodic blood work will be obtained to monitor your complete blood count (CBC) as well as the function of other organs (such as your kidneys and liver).
How Does Ixabepilone(casno.219989-84-1) Works:
Cancerous tumors are characterized by cell division, which is no longer controlled as it is in normal tissue. "Normal" cells stop dividing when they come into contact with like cells, a mechanism known as contact inhibition.  Cancerous cells lose this ability.  Cancer cells no longer have the normal checks and balances in place that control and limit cell division.  The process of cell division, whether normal or cancerous cells, is through the cell cycle.  The cell cycle goes from the resting phase, through active growing phases, and then to mitosis (division).
The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division.  Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division.  If the cells are unable to divide, they die.  The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink.  They also induce cell suicide (self-death or apoptosis).
Chemotherapy drugs that affect cells only when they are dividing are called cell-cycle specific.  Chemotherapy drugs that affect cells when they are at rest are called cell-cycle non-specific.  The scheduling of chemotherapy is set based on the type of cells, rate at which they divide, and the time at which a given drug is likely to be effective.  This is why chemotherapy is typically given in cycles.
Chemotherapy is most effective at killing cells that are rapidly dividing.  Unfortunately, chemotherapy does not know the difference between the cancerous cells and the normal cells. The "normal" cells will grow back and be healthy but in the meantime, side effects occur. The "normal" cells most commonly affected by chemotherapy are the blood cells, the cells in the mouth, stomach and bowel, and the hair follicles; resulting in low blood counts, mouth sores, nausea, diarrhea, and/or hair loss.  Different drugs may affect different parts of the body.
Chemotherapy (anti-neoplastic drugs) is divided into five classes based on how they work to kill cancer.  Although these drugs are divided into groups, there is some overlap among some of the specific drugs.
Ixabepilone(casno.219989-84-1) is an antimicrotubule agent.  It is cell cycle specific.  It acts on the microtubule structure and function of the cell by attaching to a section of the microtubule. This stabilizes the microtubular function, and stops the cell from continuing in its cycle thus causing cell death.
Ixabepilone(casno.219989-84-1) Pharmacology:
It acts to stabilize microtubules. It is highly potent agent, capable of damaging cancer cells in very low concentrations, and retains activity in cases where tumor cells are insensitive to paclitaxel.
Approval of Ixabepilone(casno.219989-84-1):
On October 16, 2007, the U.S. Food and Drug Administration approved Ixabepilone(casno.219989-84-1) for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. In November 2008, the EMEA has refused a marketing authorisation for Ixabepilone(casno.219989-84-1).
Ixabepilone(casno.219989-84-1) is administered through injection, and is marketed under the trade name Ixempra.
Clinical uses of Ixabepilone(casno.219989-84-1):
Ixabepilone(casno.219989-84-1), in combination with capecitabine, has demonstrated effectiveness in the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane.
It has been investigated for use in treatment of non-Hodgkin's lymphoma. In pancreatic cancer phase two trial it showed some promising results (used alone). Combination therapy trials are ongoing.
What Does Ixabepilone(casno.219989-84-1) Used For:
Ixabepilone(casno.219989-84-1) is used in the treatment of metastatic or locally-advanced breast cancer.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.